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Abstract 
One of the techniques utilised in the management of cancer in all stages is multiple biomedical imaging. Imaging 
as an important part of cancer clinical protocols can provide a variety of information about morphology, structure, 
metabolism and functions. Application of imaging technics together with other investigative apparatus including in 
fluids analysis and vitro tissue would help clinical decision-making. Mixed imaging techniques can provide 
supplementary information used to improve staging and therapy planning. Imaging aimed to find minimally 
invasive therapy to make better results and reduce side effects. Probably, the most important factor in reducing 
mortality of certain cancers is an early diagnosis of cancer via screening based on imaging. The most common 
cancer in women is breast cancer. It is considered as the second major cause of cancer deaths in females, and 
therefore it remained as an important medical and socio-economic issue. Medical imaging has always formed part 
of breast cancer care and has used in all phases of cancer management from detection and staging to therapy 
monitoring and post-therapeutic follow-up. An essential action to be performed in the preoperative staging of 
breast cancer based on breast imaging. The general term of breast imaging refers to breast sonography, 
mammography, and magnetic resonance tomography (MRT) of the breast (magnetic resonance mammography, 
MRM). 
Further development in technology will lead to increase imaging speed to meet physiological processes 
requirements. One of the issues in the diagnosis of breast cancer is sensitivity limitation. To overcome this 
limitation, complementary imaging examinations are utilised that traditionally includes screening ultrasound, and 
combined mammography and ultrasound. Development in targeted imaging and therapeutic agents calls for close 
cooperation among academic environment and industries such as biotechnological, IT and pharmaceutical 
industries. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Cancer is the cause of one in eight deaths 
worldwide, and about 12 million new cases are 
diagnosed yearly. In spite of using aggressive 
treatment strategies, the rate of mortality has 
remained high and thus; there need more studies 
about developing new approaches to cancer 
management [1], [2], [3]. One of the major tools used 
in comprehensive cancer care is medical imaging. It 
brings many advantages including monitoring 
capability in real time, no need to tissue destruction, 
minimal-invasive procedure, and usability over broad 
periods and size ranges that are usually needed in 
pathological and biological processes. The main factor 
in reducing mortality and cancer management costs is 
an early diagnosis. Leonard Fass [4] study showed 
that imaging through symptomatic disease 
management and screening plays an important role in 
cancer management. This is shown schematically in 
Figure 1. 
Another tool used in all stages of cancer 
management is biomedical imaging. It can be used in 
prediction, staging, screening, prognosis, biopsy 
guidance for diagnosis, plan of treatment, therapy 
guidance, therapy response recurrence and palliation 
[5], [6], [7], [8], [9]. 
Lima et al. Application of Imaging Technologies in Breast Cancer Detection 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Mar 15; 7(5):838-848.                                                                                                                                                        839 
 
 
Figure 1: The role of Imaging in cancer management [4] 
 
Translational studies link fundamental science 
to clinical applications; therefore, resulted in 
significant health consequences [3], [10] (Figure 2). 
With regards to the wide range of usage in the 
management of patients with cancer for diagnosis, 
staging, therapy planning, monitoring, and 
surveillance, imaging considered as an essential 
component of clinical cancer protocols [11]. Current 
clinical imaging techniques have some limitations 
such as using of computed tomography (CT) or 
magnetic resonance imaging (MRI) for studying in 
vivo biological changes in relation with prognosis, 
carcinogenesis and therapy response [12]. 
Full spatial mapping of gene expression and 
molecular activities within cells and tissues are 
required to get health benefits of understanding the 
genome and proteome. To this end, structural and 
functional imaging of molecules is vital. To recognise 
the existence of cancer, the tumour stage, its 
aggressiveness and response to therapy, imaging 
biomarkers are under development [13]. Several 
medicinal treatments are under development, 
classified as anti-hormonal, cytotoxic, 
immunotherapeutic and molecularly targeted. The 
molecularly targeted treatments include angiogenesis 
inhibitors, multi-targeted tyrosine kinase inhibitors, cell 
cycle inhibitors, signal transduction inhibitors, 
apoptosis inducers and epigenetic modulators [14]. 
Several targeted agents have been developed as 
cancer markers comprising of αvβ3 integrin, 
carcinoembryonic antigen (CEA), epidermal growth 
factor receptor (EGFR), vascular endothelial growth 
factor (VEGF), prostate stimulating membrane antigen 
(PSMA), somatostatin receptors, MC-1 receptor, 
folate receptors and transferrin receptors. In vitro 
imaging methods (i.e. imaging mass spectrometry 
(IMS)) by their ultra-high resolution can be used to 
specify the spatial distribution of proteins, peptides, 
and drugs in tumour tissue specimens. The main 
focus of this review is the clinical imaging methods [8]. 
Developments in our ability to analyse 
molecular processes, such as gene and protein 
expression, cellular and molecular biochemistry, make 
it possible of a better understanding of breast cancer 
biology and recognition of new therapies for patients 
[15]. Measuring biological processes in vivo without 
disturbing them, helps in better characterisation of 
tumour biology. It also lets us evaluate the way 
biological, and cytotoxic therapies change key 
pathways through which tumour responds and 
generate resistance. Molecular imaging can carefully 
characterise the properties of the tumour, and 
biological processes hence play an important role in 
clinical care from detection to staging, breast cancer 
knowledge, evaluation of therapeutic objectives, and 
assessment of responses to various therapies [16]. 
 
Figure 2: Map of translational research based on practice. (The 
working model of bench-to-bedside translational research is 
described in this diagram); Forward Translation: Molecular 
explorations translated into the clinical application; Reverse 
Translation: Scientific questions arise from relevant clinical findings 
resulted in research progress 
 
The elasticity of cancer tissues is lower than 
normal tissues. This difference in elasticity makes 
ultrasound elastography suitable to the differential 
diagnosis of prostate cancer, liver fibrosis and breast 
cancer [17], [18]. Lots of clinical imaging systems 
work based on the different response of body tissues 
and fluids to electromagnetic radiation. But ultrasound 
works through frequency variation, dispersion and 
reflection of acoustic waves. The interaction of 
ultrasound and tissues makes it able to illustrate 
tissue elasticity. Another application of ultrasound is in 
thermal therapy, and its mediating ability of gene 
expression and gene transfer is well known [19]. 
Imaging of pancreatic masses, lymph nodes, adrenal 
and submucosal tumours by endoscopic ultrasound 
elastography is possible and can avoid fine needle 
aspiration biopsies [20]. 
In their study about breast cancer imaging 
techniques, Poplach et al., [21], [22] stated that 
imaging techniques based on non-ionizing 
electromagnetic radiation such as microwave imaging 
spectroscopy and near-infrared spectroscopy among 
others had been mainly investigated for breast 
imaging. However physical properties of imaging 
systems involving sensitivity, temporal and spatial 
resolution are different. The most sensitive clinical 
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imaging techniques are PET and nuclear medicine 
which their sensitivity varied from nanomole/kilogram 
to picomole/kilogram. The sensitivity of X-Ray 
systems such as CT is millimole/kilogram whereas the 
sensitivity of MR is around 10 µmol/kg [23]. 
Because cancer is a disease with multiple 
factors, imaging has to display the variant 
mechanisms and stages of pathogenesis. Tumour 
volume characteristics can only show response delay 
to therapy and can't indicate the metabolism and other 
parameters. Thus its application alone as a measure 
of disease development is not inadequate. That’s the 
reason for using multiple imaging methods for 
managing cancer. Multiple imaging techniques such 
as PET/CT incorporates the benefits of PET (i.e. 
metabolic sensitivity) and CT (i.e. temporal and spatial 
resolution). Integration of imaging techniques such as 
SPECT/CT, PET/CT, PET and MR and ultrasound 
and MR in the future will require developing standard 
approaches to perform longitudinal studies about the 
response to therapy [25]. 
At last, integrating various imaging 
technologies will lead to diagnostic orthogonality. It is 
supposed that the combination of such information not 
only provides a mean to validate individual 
technologies in the future but also forms a part of the 
diagnostic process, particularly for prediction, early 
detection and early therapy response of the disease 
[17]. In this review, the most recent technologies in 
the world’s newest research studies are introduced. 
Also, new scientific methods for the examination, 
diagnosis and evaluation of benign and malignant 
tumours are presented. 
 
Digital imaging systems 
Full field digital mammography is one of the 
helpful digital imaging systems for breast cancer 
diagnoses. It has several privileges over film-based 
techniques for screening of breast [26] including 
increased dynamic range, improved sensitivity for 
dense breasts, lower dose, digital archiving, 
computer-aided detection/diagnosis, telemedicine, 
tomosynthesis, softcopy review, 3-D visualisation 
techniques and reducing breast compression 
pressure. Overlapping and obscuring malignancies by 
normal structures like glandular tissue in the breast, 
particularly those placed deep in the breast is a 
potential constraint of 2D mammograms. This can 
cause cancers to be skipped in the scan. 
On the contrary, overlapping normal tissues 
can be misunderstood with tumours in an X-ray image 
and caused extra imaging, performing unessential 
biopsies, higher costs of healthcare and patient 
anxiety. The combination of tomosynthesis and digital 
mammography can result in lower false negatives and 
increasing true positives [27]. Also, using 3D X-ray 
techniques along with tomosynthesis can reduce 
breast compression. Other 3D methods to produce 
stereoscopic images are available. Digital X-ray 
images of the breast taken at two different angles by 
about eight degrees’ difference can produce 
stereoscopic mammograms. The radiologist through 
these images can see the breast interior structure in 
three dimensions and make better distinguish 
between benign and malignant lesions. Accordingly, 
one can say that this technique has a greater 
detection rate and lower false positives compared to 
regularly 2D mammography [28]. In the other side, a 
higher number of images in this technique increases 
the risk of exposure high radiation dose. 
Jong [29] stated that Contrast-enhanced 
mammography is an investigational technique that 
uses iodinated contrast agents. This technique is built 
on the principle that the quick growth of tumours 
necessitates enhanced blood reserve across 
angiogenesis. If the compression device is not 
activated, then contrast should be administered. 
Angiogenesis regions resulted in the accumulation of 
the contrast agent. Diekmann and Bick [30] uttered 
that contrast-enhanced mammography with tom 
synthesis is an imaging contrast distribution technique 
in breast tissue. There are two methods to evaluate 
images. The first one is to look for maximum iodine 
concentration in the image, generally 1 minute after 
injection. The regions with high absorption 
demonstrate the growing activity of tissues, and likely 
the malignant ones. The kinetic analysis technique 
can track iodine contrast agent flow inside of a tissue 
region and outside of it. The speed of wash-in and 
wash-out of iodine in malignant cancers is high, while 
iodine uptake of benign tissues is slow, took about 5 
min in this study. This is identical with perfusion 
imaging by MRI using gadolinium-based contrast 
agents. 
Dual-energy contrast mammography has the 
ability of better breast lesions diagnosis at lower 
radiation doses than non-contrast enhanced 
mammography, but this is not identified for contrast-
enhanced MRI and needs to be evaluated. 
Combination of tomosynthesis with contrast-enhanced 
mammography may lead to better detection of 
preliminary and secondary lesions and also the 
potency to monitor therapy [31], [32]. 
To enhance lesion detection efficiency, 
computer-aided detection (CAD) is used. Dual-energy 
techniques have some advantages include removing 
the structural noise, contrasting media that magnify 
the area around the tumour, and improving lesions 
detectability. CAD aims to facilitate recognise lesions, 
particularly in locations where obtaining a second 
reading is difficult. CAD is more suitable for 
recognising micro-calcifications but less effective for 
breast masses. Competent breast cancer experts who 
are capable of differentiating benign lesions from 
malignant ones can better utilise CAD [33]. CAD has 
great sensitivity for breast cancer detection on initially 
and short-term follow-up digital mammograms. 
Reproducibility for true positive CAD marks is 
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significantly higher than for false positive ones [34]. 
Recently, a mega-study composed of 231,221 
mammograms showed that CAD improves the 
efficiency of the single reader and increases 
sensitivity just with a little increment in recall rate [35]. 
Increased sensitivity and specificity is 
possible using dual modality systems that combine 
ultrasound and X-ray systems [36]. Mammography 
has no sensitivity in imaging young compact breasts 
because the encompassing fibroglandular tissue 
decreases the manifestation of lesions. Moreover, 
screening by ultrasound can considerably increase 
the detection rate of small cancers. Also it can 
represent considerably more cancers at a smaller size 
and lower phases compared to physical examination 
alone, which identifies hardly any cancers. Increasing 
breast compression that is naturally greater in older 
women with dense breasts significantly declines the 
mammographic sensitivity for breast cancer. The 
detection sensitivity of full field digital mammography 
systems for dense breasts is better than film-based 
systems. The American Cancer Society recommends 
that even women with a good health condition should 
continue screening mammography [37]. 
 
Breast Cancer Magnetic resonance 
imaging (MRI) 
The application of magnetic resonance 
systems in cancer detection, monitoring therapy 
response, staging, least-invasive therapy guidance 
and biopsy guidance has been documented [38]. 
Imaging techniques using in cancers are based on 
diffusion-weighted imaging, perfusion imaging using 
contrast agents, exogenous spectroscopic imaging 
with hyperpolarised contrast agents, endogenous 
spectroscopic imaging, blood oxygen level 
determination (BOLD) imaging, magnetic resonance 
elastography, relaxivity-based imaging with and 
without contrast agents [39]. 
The first investigators who used MRI for 
breast cancer examination were Ross et al., [40]. 
Today, breast MRI is considered as a supplementary 
technique along with ultrasound and mammography. 
So, MRI technology of the breast has greatly 
improved by the extension of advanced surface and 
gradient coils, contrast agents, parallel imaging and 
novel fast imaging sequences. Simultaneous imaging 
of both breasts are possible using new surface coils, 
allows indicating involvement of the contralateral 
breast. Breast MRI sensitivity for breast cancer 
detection is higher than ultrasound or mammography. 
Because of high expenses, hard accessibility, and 
high false positives of MRI, it is not widely used as a 
screening test for breast cancer, but in special cases 
[41]. Breast MRI is not based on ionising radiation. As 
a result, it is suggested in the repeated screening of 
patients with high risk of radiation-induced DNA 
mutations. Breast MRI is applied to screen women 
with very dense breast tissue, women with a family 
background of breast cancer, or women with silicone 
implants that may conceal pathology in 
mammography. It can also be used for seeking 
recurrence in patients with scar tissue. The American 
Cancer Society has strongly confirmed using MRI to 
identify contralateral disease extension and lymph 
node involvement in breast cancer [37]. 
Because of its ability to show multi-focal 
tumours, chest wall involvement, retraction of the skin 
and lymph node metastases, MRI is the most 
accurate instrument for the local staging of breast 
cancer. Compared to other methods, it performs 
better in imaging invasive lobular carcinoma. Magnetic 
resonance imaging due to its ability in easier 
analysing of pathological response as well as a low 
rate of reoperation needed for positive margins is 
preferable than mammography and ultrasound [42]. 
This suggests one important role of MRI, i.e. facilitate 
decision-making about performing conserving surgery 
or mastectomy. 
Strong paramagnetic nature of gadolinium 
makes it possible to alter the magnetic situation of 
hydrogen atoms inside water molecules. High 
concentrations of gadolinium components due to 
susceptibility effects resulted in local changes in the 
magnetic field. Dynamic studies of wash-in and wash-
out are possible using contrast-enhanced MR. The 
maximum effect is accrued after rapid intravenous 
injection during the first passage of a bolus of contrast 
agent. This creates darkness on gradient echo T2*-
weighted images in highly perfused areas of tissues. 
But tissues with a high contrast agent uptake appear 
bright on T1-weighted images. 
Takayoshi et al., [43] argued that myocardial 
perfusion imaging could be used in the assessment of 
two-sided micro-calcifications following by stereotactic 
vacuum-assisted biopsy. They further stated that it 
could illustrate the existence of malignant micro-
calcifications seen on mammography. Naoyo Nishida 
et al., [44] declare that evaluating neo-angiogenesis 
requires using dynamic contrast MRI with gadolinium-
based contrast agents that is related to microvessel 
density, histopathology and response to 
chemotherapy [45], [46], [47]. The time/signal intensity 
graphs at the maximal enhancement site for each 
progression lesion are achieved closely. Three types 
of time/signal intensity curves identified by Riham H. 
et al., [48] as below:  
(I) continual enhancement curves are 
normally related to benign lesions.  
(II) Curves with a quick contrast uptake 
following with a plateau state can be representative of 
both benign and malignant lesions.  
(III) Curves with a quick contrast uptake and 
wash-out are usually pertained to malignant lesions. 
Using agents that block angiogenesis, MR 
perfusion imaging can be used directly and indirectly 
to monitor therapy. Because of the potential ability of 
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anti-angiogenic therapy in temporarily normalising the 
abnormalities in structure and function of tumour 
vascular system, it can terminate angiogenic blood 
vessels. Due to the less permeability of normalised 
blood vessels, their efficacy in drug and oxygen 
delivery is better. Pericytes that are vascular smooth 
muscle cells has an essential role in blood vessel 
formation. Further, they can help the normalised 
vessels to remain strong [49]. The strong vessels can 
diminish the intravasation of cancer cells, hence 
decrease the risk of haematogenous metastasis. 
Severity time curves for various breast tissues are 
illustrated in Figure 3. 
 
Figure 3: Time/severity curves of breast MR contrast uptake 
(derived from; Riham H. et al., [48]) 
 
American Breast Imaging Reporting and 
Database system [50] has declared that enhancement 
of heterogeneous or rim is an indication for 
malignancy and irregularly shaped speculated 
masses. Nunes [51], on the other hand, stated that a 
nonmass asymmetrical enhancement with a 
segmental or regional pattern could be considered as 
a powerful symptom of in situ ductal carcinoma. 
Liberman et al. [52] reported in their study that non-
enhancing septa or smooth borders which are 
observed in many fibroadenomas suggest benign 
lesions. They further stated that small lesions with the 
size of smaller than 5 mm often have no clinical 
significance. 
 
Diffusion-weighted imaging Method 
Diffusion-weighted imaging (DWI) MRI 
formerly used in cytotoxic oedema detecting in stroke. 
Today, it is also used to measure Brownian movement 
(the diffusion of water molecules). It is expected that 
this technique can be used for the identification of 
tumours and metastases as well as classifying breast 
lesions as benign or malignant [53]. Both quantitative 
and qualitative information on the changes developed 
at a cellular level can be obtained using DWI MRI. 
This information shows the effect of cell membrane 
integrity and tumour cellularity. Thanks to recent 
advancements, this technique is extensively applied 
for tumour assessment inside the body and have 
developed whole body DWI. Here is an example of 
osseous and soft tissue metastatic lesions; Figure 4-1 
and 4-2 illustrate a 42 years old female with breast 
cancer and massive metastatic nodal spread along 
some parts of her body that was presented with lower 
back pain, right sciatica [54]. 
 
Figure 4-1. An instance case of metastatic breast cancer; A) The 
anterior and posterior projections of the patient, focal zones of hot 
uptake at D1, L2 and right aspect of the manubrium sterni are 
shown in a bone scan; B) Sagittal T1W image of the dorsolumbar 
spine. A sizable hypointense marrow lesion can be seen in the right 
posterolateral aspect of the L2 vertebra. 
Further, a pedicle with expansion and extra-osseous soft tissue 
component are demonstrated; C) Axial T2W image at L2 level. 
Right sided infiltrative process with intra and retrospinal soft tissue 
extensions are shown; D) Sagittal T1W image of the cervical spine. 
Hypointense metastatic lesions at C5 and D1 are demonstrated 
 
According to Galbán et al., [55], tumour 
tissues cause a disruption in water molecule diffusion, 
as a result, the rate of apparent diffusion constant 
(ADC) reduces, resulted in high signal in DWI images. 
Positive response to therapy is represented by a rise 
in ADC. The number of killed cells is directly related 
with increase of water ADC after therapy. Water 
liberation into the extracellular space in result of cell 
necrosis is a possible cause of this relationship. 
 
Figure 4-2: The previous case of metastatic breast cancer; A) WB-
MRI coronal T1W image. The primary breast lesion can be seen at 
upper inner quadrant of the right breast. It is showed by dark signal 
and irregular outlines; B) Corresponding axial inverted DWI. Breast 
lesion are shown as a flared out zone of evident diffusion restriction. 
The mean ADC value of the zone is 0.91 x 10-3 mm2/sec; C) & D) 
Axial inverted DWI at different levels. The pulmonary nodules are 
shown as rounded focal zones of diffusion restriction at lateral 
segment of right middle lung lobe C) and posterior segment of left 
lower lung lobe D) giving a low mean ADC value ranging between 
0.97 and 1.03 x 10-3 mm2/sec 
 
Buijs et al., [56] stated that response 
evaluation of metastatic breast cancer to 
chemoembolization is possible by ADC Measurement. 
ADC values of normal tissues would not change, 
whereas this value for tumor tissue showed an 
increase after transarterial chemoembolization. In the 
other hand, a full response cannot be obtained in solid 
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tumors using MRI, even if volume changes viewed 
with contrast-enhanced. Response to radiation 
therapy in the cases with High DWI MRI may be 
possible [37]. The response of tumours having a high 
diffusion constant due to their wide necrotic region is 
worse. Palpation is applied as a part of the clinical 
diagnosis of prostate, thyroid, breast and abdominal 
pathologies. It determines the rigidity of a region 
compared to the nearby tissues. The regions with 
increased ADC are obtained by partial responders. 
Whole-body MRI is comparable with PET/CT and 
scintigraphy in the identification of sclerotic 
metastases, which are usual processes in breast and 
prostate cancers as well as multiple myeloma. 
Currently, PET/CT is applied for soft-tissue metastatic 
disease, while diffusion-weighted MRI methods have 
the potential to be used in the future. 
 
Magnetic resonance elastography 
Magnetic resonance elastography (MRE) by 
transmission of shear waves and imaging their 
propagation using MRI, measures the mechanical 
characteristic (stiffness) of soft tissues [57]. It is a non-
invasive medical imaging technique. The stiffness of 
diseased tissues is often more than the normal tissues 
around it. This is done while the application of 
acoustic waves by adjusting motion-sensitive phase 
contrast MRI sequences. The range of acoustic waves 
frequencies is among 100 Hz to 1 kHz. Propagation of 
shear waves is a function of the shear modulus of the 
tissue [58]. MRE produces images of shear wave 
propagations with variable wavelengths. Some 
researchers based on these criteria have investigated 
the application of MRE in breast cancer detection as a 
constant method of detection. They reported that; 
breast cancer tissues are much harder than healthy 
fibroglandular tissue. Physicians used this 
characteristic for screening and diagnosis of many 
diseases, through palpation. MRE, through a non-
invasive and objective way, calculates the mechanical 
parameter while elicited by palpation, [59], [60], [61]. 
 
Apoptosis/Receptor imaging 
Binding agents to cell surface proteases that 
attract phagocytes to dying cells are also used to 
direct imaging of apoptosis. To perform optical and 
nuclear medicine imaging, Annexin V has been 
utilised. Zhao et al., [62] reported the using of targeted 
super-paramagnetic iron oxide (SPIO) to perform 
receptor imaging. This is a practical method for breast 
cancer imaging. Artemov et al., [38], for example, 
used targeted iron oxide to image tyrosine kinase Her-
2/neu receptor in breast cancer cells. The targeted 
agent used to MR contrast was Streptavidin-
conjugated super-paramagnetic nanoparticles. 
Boosted T2 MR contrast were generated for Her-
2/neu-expressing cells via directing these 
nanoparticles to receptors which previously classified 
as a biotinylated monoclonal antibody. The expression 
level of Her-2/neu receptors governs the contrast of 
MR images. The level of expression attained 
independently using fluorescence-activated cell 
sorting (FACS) analysis. One of the limitations of MRI 
for direct imaging is its sensitivity but could utilize in 
pre-clinical imaging. Such target-mediated imaging is 
successfully applied in nuclear medicine imaging, 
include imaging of breast cancer tumours [63], [64]. In 
this method, the molecular expression pattern of 
tumours is targeted. Synthesised target ligands 
composed of antibodies, peptide analogues, 
nanobodies and affibodies can target those molecules 
(for example, enzymes, transporters and receptors) 
overexpressed on cancer cells. They stick to the 
target with high affinity and specificity (Figure 5). 
 
Figure 5: Schematic of receptor targeted nuclear imaging. Ligands 
can bind those targets that are overexpressed on breast cancer 
(BC) cells. These ligands can be joint to a chelator, mostly by a 
linker 
 
Magnetic Resonance Spectroscopy 
An additional technique to improve the 
accuracy of a breast MRI study is Magnetic resonance 
spectroscopy (MRS). Following conventional MRI 
imaging of a breast, a chemical “spectrum” is 
evaluated in a suspicious region to provide additional 
information about the chemical content of that region. 
This information can be used to distinguish benign 
from malignant masses, and to determine the faster 
respond of a mass to chemotherapy treatments and 
MRI alone [65]. The molecules such as hydrogen ions 
or protons are analysed in MRS, but the more 
common method is Proton spectroscopy. Localising 
tumours, detecting a response to therapy and 
directing biopsies in the breast are the potential role of 
Spectroscopic imaging and 3D MR proton 
spectroscopy [66]. Integrating MR spectroscopic 
imaging with MR anatomic imaging lets to localise the 
spatial position of metabolites. The main phospholipid 
in cell membranes is Choline. It is known as a 
potential marker of cell division and helps in 
phosphatidylcholine formation. According to Chung-
Ho et al., [67], the present of carcinogenesis in human 
breast epithelial cells causes membrane choline 
phospholipid metabolism to be changed progressively. 
Yeung et al., [68] in their study about the application 
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of proton MR spectroscopy in preliminary 
observations and specifying of histopathologic 
subtypes in axillary node metastases of breast cancer, 
noticed that high choline levels are related to 
increased lymph node metastases and invasive ductal 
carcinomas of the breast. An example of proton 
spectroscopy for a breast lesion on MRI and the 
corresponding MRS spectrum is illustrated in Figure 6 
[69]. 
 
Figure 6: Imaging of a breast lesion using MRI anatomic image and 
proton spectroscopy. (Derived from; Haddadin et al. [69]); A) 
Magnetic resonance spectroscopy derived from a post-contrast 
gradient echo MRI of a 51-year-old woman with invasive ductal 
carcinoma; B) Detected Areas with doubtful masses; C) The 
resonances of corresponding water and lipid suppressed spectrum 
acquired 
 
Bartella and Huang [70] further showed that 
monitoring and predicting response to chemotherapy 
as well as reducing the number of breast biopsies is 
accessible, provided that choline levels are used to 
differentiate benign from malignant tumours. Change 
monitoring in these metabolites can help to observe 
therapy response or malignant transformation. Owing 
to the low concentration of these isotopes inside 
tissues, the obtained signal is weak, and also, 
acquisition of signals takes very long times. As a 
result, clinical application of spectroscopy of 
endogenous has been limited [71], [72]. 
 
Breast Ultrasonography 
Ultrasound is an imaging examination. 
Application of ultrasound in the detection of tumours in 
the breast, thyroid, prostate, pancreatic, liver, uterine, 
ovarian, and kidney is very common and is considered 
as a common diagnostic imaging method. During 
performing the ultrasound test, sound waves with high 
frequency passed across the breast and turned into 
images that are shown on a display screen. 
Ultrasound is used to complete other screening tests 
and is not a screening test for breast cancer by itself 
[73]. When observing an abnormality on 
mammography, or when felting it by physical 
examination, the best method to identify whether the 
irregularity is rigid (for example, a benign 
fibroadenoma or cancer) or fluid-filled (such as a 
benign cyst) is performing an ultrasound test. 
Ultrasound cannot be used to determine if a solid 
lump is cancerous. Visualisation of lesions is 
enhanced in volume ultrasound. Another main 
application of ultrasound is to guide biopsies. With no 
need to ionising radiation, ultrasound is suitable for 
follow up studies to check for recurrence [74]. Some 
of the recent developments in ultrasound include 
ultrasound elastography, targeted microbubble 
contrast agents, photoacoustic imaging and locally 
activated ultrasound [73], [75]. 
 
Breast Scintimammography 
Specialising imaging systems would be an 
area of developments in the context of nuclear 
medicine in future. Development of specialised 
gamma cameras, for example, could help in imaging 
of breast and axillary nodes by the use of 
scintimammography. This is because of the need to 
prevent dispersing from extra-mammary sources and 
has a significant role in breast imaging using 
radiotracers. It is also the prevailing effect when 
imaging near the chest wall by the use of 
mammoscintigraphy [76]. Another technique for breast 
imaging is Scintimammography. It is used to identify 
cancer cells in women breasts who have abnormal 
mammograms, or those with post-operative scar 
tissue, dense breast tissue, or breast implants. 
Radiopharmaceuticals images for scintimammography 
are taken using traditional gamma cameras that are 
also called a large field of view cameras [77]. Due to 
the large passive area at the edge of these camera 
detectors that prevents it from imaging breast tissue 
closing to the chest wall, scintimammography is 
generally performed either in patient's supine position, 
and the camera takes a lateral image of the breast, or 
in the prone position so that the breast hangs freely. 
Therefore, with no breast compression, the sensitivity 
for detecting smaller lesions is decreased [78], [79], 
[80]. Breast Mammography and scintimammography 
of carcinoma used in the scintimammography in a 
woman are shown in Figure 7. A woman in the figure 
received a small amount injection of a radioactive 
substance which is absorbed by cancer cells. A 
gamma camera is used to image the breasts [81]. To 
overcome the restrictions of traditional 
scintimammography, specific breast-specific gamma 
camera imaging (BSGI) systems have been 
developed. The cameras using in these systems have 
a narrow field of view, causing improved flexibility of 
movement and increased resolution in comparison to 
conventional gamma cameras [76]. 
 
Figure 7: Ductal carcinoma in situ of the left breast, comedo, solid 
and cribriform type [81]. A) Mammography, medio-lateral projection. 
Microcalcifications (transparent arrow) behind the nipple; B) Scinti-
mammography, left lateral projection: 99m Tc-(V) DMSA at 10 min 
and 60 min (i-ii) 
 
Brem et al., [79] argued that the sensitivity of 
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a specific gamma camera to detect breast cancer in 
patients with two-sided mammograms is comparable 
to MRI. Sweeney and Sacchini [82], on the other 
hand, believed that this superiority is because of using 
breast-specific gamma camera imaging system. Some 
recommendations for scintimammograph application 
in recent studies are as follows: 
- In patients having lesions with a low 
probability of malignancy who referred for biopsy. 
- In patients with breast cancer who their 
disease is confirmed to detect axillary lymph node 
metastases. 
- As an additional test to mammography in 
patients who have palpable masses or suspicious 
mammograms to distinguish benign and malignant 
breast lesions. 
- In patients whom mammography showed 
the benign probability, and are recommended for 
repeating mammography (in 3-6 months). 
- In patients whose, dense breast tissue is 
found on mammography but is hard to evaluate it on 
mammography. 
 
 
Conclusion 
 
One of the techniques utilised in all stages of 
cancer management is multiple biomedical imaging. 
Imaging as an important part of cancer clinical 
protocols can provide a variety of information about 
morphology, structure, metabolism and functions. 
Application of imaging technics along with other 
detective apparatus including in vitro tissue and fluids 
analysis would help clinical decision-making. Mixed 
imaging techniques can provide supplementary 
information used to improve staging and therapy 
planning. Imaging aimed to find minimally invasive 
therapy to make better results and reduce side 
effects. Some of the research areas with the potential 
of clinical use in the next decade include gene therapy 
expression, targeted imaging of receptors, and cancer 
stem cells. Further development in technology will 
lead to increase imaging speed to meet physiological 
processes requirements. Development in targeted 
imaging and therapeutic agents calls for close 
cooperation among academia and industries 
(biotechnological, IT and pharmaceutical industries). 
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